Ticagrelor reversal agent achieves quick hemostasis: REVERSE-IT
November 17, 2021
The monoclonal antibody bentracimab, which can rapidly reverse ticagrelor, was found effective and safe in an FDA-requested interim analysis of a phase 3 trial.
EHRs have no impact on inpatient heart failure clinical choices or outcomes
November 15, 2021
Relative to usual care, prognostic information at the bedside provided no advantage for heart failure care.
Troponin elevation at any age is a risk for cardiac mortality
November 15, 2021
Is an elevated troponin value associated with increased mortality, regardless of age?
BP Track: Blood pressure control rates dropped during pandemic
November 14, 2021
Data culled from 24 health systems showed lower rates of blood pressure control during the COVID-19 pandemic.
ASNC rejects new chest pain guideline it helped create
November 2, 2021
“We believe that the document fails to provide unbiased guidance to health care professionals on the optimal evaluation of patients with chest pain.”
AHA/ACC issues first comprehensive guidance on chest pain
October 29, 2021
The clinical practice guideline offers a contemporary approach to determine which patients need further testing and which do not.
New prescription for loop diuretic improves 30-day heart failure outcomes
October 22, 2021
Does a new prescription for a loop diuretic improve short-term outcomes in patients hospitalized for heart failure?
No benefit from lower temps for out-of-hospital cardiac arrest
October 20, 2021
The results “do not support the use of moderate therapeutic hypothermia to improve neurologic outcomes in comatose survivors of out-of-hospital cardiac arrest.”
Some diabetes drugs may lower risk of severe COVID-19 outcomes
October 19, 2021
Glucose-regulating medications may improve outcomes in COVID-19 patients with type 2 diabetes, a multinational retrospective cohort study suggests.
Omega-3s tame inflammation in elderly COVID-19 patients
October 13, 2021
Those who received an intravenous infusion had significant decreases from baseline to end of treatment in the neutrophil-to-lymphocyte ratio.